Celldex Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option

Celldex Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale has defended clients in hundreds of class, derivative, shareholder and individual actions alleging securities fraud, breach of fiduciary duty and other corporate misconduct.

Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) announced the closing of its previously announced underwritten public offering of 11,896,750 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,551,750 shares of common stock at a public offering price of $29.00 per share. All of the shares sold in the offering were sold by Celldex. The gross proceeds to Celldex from this offering were approximately $345 million, excluding underwriting discounts and commissions and other offering-related expenses.

WilmerHale represented the underwriters in the public offering.

The WilmerHale team was led by Lisa Firenze, and included Andrea Sorrentino, Rachael Joseph, Amy O’Connell, Barish Ozdamar, and Bruce Manheim.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel